Clonazepam

# clonazepam ## Overview - **Classification**: Benzodiazepine, anxiolytic, anticonvulsant. - **Mechanism**: Enhances the inhibitory effects of gamma-aminobutyric acid (GABA) at GABA-A receptors in the CNS. ## Primary Indications 1. **Seizure Disorders** - Management of Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. 2. **Panic Disorder** - Treatment of panic disorder, with or without agoraphobia. ## Adult Dosing ### Standard Dosing **Seizure Disorders** - **Dose**: Initial **0.5 mg/day** - **Frequency**: Administered at night or in 2-3 divided doses - **Route**: Oral - **Titration**: Increase by **0.5-1 mg** every 3 days until controlled. - **Maximum Dose**: **20 mg/day** **Panic Disorder** - **Dose**: Initial **0.25 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Titration**: Increase by **0.125-0.25 mg/day** every 3 days. - **Maintenance Dose**: **0.5-4 mg/day** - **Maximum Dose**: **4 mg/day** ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments for mild-moderate. Use with caution in severe impairment due to metabolite accumulation. - **Hepatic Impairment**: **Reduce dose** significantly. Contraindicated in severe liver disease. Monitor closely for CNS effects. - **Elderly Patients**: Start with **lowest possible dose** (e.g., **0.25 mg once daily or BID** for panic disorder). Increased sensitivity to CNS depressant effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not generally recommended due to high risk of respiratory depression. - **Special Notes**: Use only in severe, refractory cases under expert supervision. ### Infants (1-12 months) - **Indication**: Seizure disorders (akinetic/myoclonic/Lennox-Gastaut). - **Dose**: Initial **0.01-0.03 mg/kg/day** - **Frequency**: Divided into 2 or 3 doses. - **Titration**: Increase by **0.25-0.5 mg** every 3 days. - **Maximum**: **0.1-0.2 mg/kg/day** or **10 mg/day**, whichever is less. - **Special Notes**: Monitor closely for sedation and respiratory depression. ### Children (1-12 years) - **Indication**: Seizure disorders (akinetic/myoclonic/Lennox-Gastaut). - **Dose**: Initial **0.01-0.03 mg/kg/day** - **Frequency**: Divided into 2 or 3 doses. - **Titration**: Increase by **0.25-0.5 mg** every 3 days. - **Maximum**: **0.1-0.2 mg/kg/day** or **10 mg/day**, whichever is less. - **Formulation**: Oral tablets can be crushed or liquid formulations may be available. ### Adolescents (13-18 years) - **Approach**: Dosing similar to adult recommendations. - **Seizures**: Initial **0.5 mg/day** at night or divided. Titrate up to **20 mg/day** max. - **Panic**: Initial **0.25 mg BID**. Titrate up to **4 mg/day** max. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to benzodiazepines. - **Absolute**: Acute narrow-angle glaucoma (unless receiving appropriate treatment). - **Absolute**: Severe liver disease. - **Absolute**: Co-administration with opioids (Black Box Warning due to respiratory depression risk). ### Common Adverse Effects - **Very Common (>10%)**: Drowsiness, sedation, ataxia, dizziness. - **Common (1-10%)**: Fatigue, cognitive impairment, blurred vision, slurred speech. - **Serious but Rare**: Respiratory depression, paradoxical reactions (e.g., agitation, aggression), suicidal ideation. ### Key Drug Interactions - **Opioids**: Increased risk of respiratory depression, profound sedation, coma, death. **Avoid concomitant use**. - **Other CNS Depressants (alcohol, barbiturates, antihistamines)**: Additive CNS depression. Avoid or use with extreme caution. - **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin)**: May decrease clonazepam levels and efficacy. Monitor for loss of effect. - **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole)**: May increase clonazepam levels. Monitor for increased sedation. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline hepatic and renal function (if risk factors), psychiatric history. - **During Treatment**: Monitor for CNS depression (sedation, ataxia), respiratory status, seizure control (if applicable), and mental status changes. - **Clinical Signs**: Watch for signs of abuse, dependence, or withdrawal (if discontinuing). Monitor for worsening depression or suicidal ideation. ## Clinical Pearls - 💡 **Tip 1**: Taper dose slowly over several weeks to avoid withdrawal symptoms (e.g., rebound seizures, anxiety, insomnia). - 💡 **Tip 2**: Initial sedation is common; advise patients to take the first dose at bedtime. Avoid driving or operating machinery. - 💡 **Tip 3**: Not for long-term use in most cases due to risk of tolerance and physical dependence. Reassess need periodically. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.